Observational studyBMC infectious diseases2025
Advanced lung cancer inflammation index and all-cause mortality in critically ill patients with sepsis: analysis of the MIMIC-IV database.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of the Advanced Lung Cancer Inflammation Index for Predicting in-Hospital Mortality in Intensive Care Unit Patients with Septic Shock: A Retrospective Cohort Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe advanced lung cancer inflammation index (ALI) has been shown to associate with the outcome in many diseases. This study aimed to explore the association between ALI and all-cause mortality in critically ill patients with sepsis.
methodsThis is a retrospective observational cohort study and data are obtained from the Medical Information Mart for Intensive Care-IV (MIMIC IV 3.0) database, which included 8133 patients with sepsis and had the measurement of ALI. The participants were divided into four groups based on the quartiles of ALI. The study endpoints were 30-day and 360-day all-cause mortality.
resultsA total of 8133 patients were included in this study. The mortatliy decreased as ALI increased from Q1 to Q4 group. Multivariable Cox regression analysis observed compared with patients in Q1, patients in Q2, Q3, and Q4 had reduced risk of 30-day all-cause mortality (Q2 vs. Q1 HR = 0.871, 95%CI 0.779, 0.974, p = 0.015; Q3 vs. Q1 HR = 0.779, 95%CI 0.689, 0.881, p < 0.001; Q4 vs. Q1 HR = 0.753, 95%CI 0.660, 0.858, p < 0.001) and 360-day all-cause mortality (Q2 vs. Q1 HR = 0.886, 95%CI 0.809, 0.971, p = 0.009; Q3 vs. Q1 HR = 0.810, 95%CI 0.734, 0.894, p < 0.001; Q4 vs. Q1 HR = 0.780, 95%CI 0.702, 0.868, p < 0.001). Restricted cubic spline analysis revealed a non-linear association between ALI and 30-day and 360-day all-cause mortality and the risk increased more significantly as ALI decreased when ALI < 7.961. Sensitivity analysis indicated that the effect of ALI on different subgroup patients were consistent except in patients with or without liver disease.
conclusionALI was negatively associated with short-term and long-term all-cause mortality in patients with sepsis. ALI could serve as a marker for risk stratification and the subsequent interventions in patients with sepsis. However, more studies are warranted to validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.